Family s anguish as woman died at Frimley Park Hospital four days after knee operation getsurrey.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from getsurrey.co.uk Daily Mail and Mail on Sunday newspapers.
John McKno who died at HMP Norwich in September 2019. Picture: Suffolk Police
- Credit: Suffolk Police
Staff have been criticised in a report for not attempting to resuscitate a paedophile maths teacher who died in prison after choking on his breakfast.
A post-mortem report concluded that McKno died from breathing in the contents of his stomach due to choking on food in his oesophagus.
The Prison and Probation Ombudsman (PPO) report said McKno had a Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) order.
It said: The clinical reviewer’s most significant concern was the decision not to attempt to resuscitate McKno. She found that there was a failure to follow the Resuscitation Council’s guidelines which make it clear that choking is not a reason for not attempting resuscitation.
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Todos Medical starts trial of protease inhibitor to treat Covid-19 20 Apr 2021 (Last Updated April 20th, 2021 10:48)
Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients.
Share Article
Todos Medical has started a Phase II clinical trial to evaluate the safety and efficacy of its antiviral NLC-V-01 (Tollovir), a potent 3CL protease inhibitor to treat hospitalised Covid-19 patients.
The 77-patient, randomised, double blind, placebo-controlled trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel.
Todos Medical is developing the therapeutic agent Tollovir through a joint venture with NLC Pharma.
In addition, the secondary endpoints of the trial being examined are:
Rate of change of measured parameters
Rate of change in vital signs (blood pressure, heart rate, respiratory rate, saturation, and body temperature)
Time from the 1st day of receiving NLC-V treatment to negative RT-PCR test result
COVID-19 related deaths
Incidence and duration of time on supplemental oxygen
“I am glad that my pioneering academic work over the last 30 years on 3CL mechanisms has made such a significant impact, and that it is finally being recognized by leading pharmaceutical companies as a key target in the war against COVID-19 that could yield an easy to administer oral antiviral therapeutic capable of stopping SARS-CoV-2 replication, independent of different mutations that are emerging at the site of spike protein,” said Dr Dorit Arad, co-founder and chief scientific officer of NLC Pharma in a statement.